SCHEMBL3392158

SCHEMBL3392158

Cc1ncccc1C(=O)N[C@@H]1CCc2ccccc2C1

nearest known ligand 0.57

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 4/20 0.57
MTNR1B P49286 4/20 0.57
P2RX7 Q99572 1/20 0.49
RAB9A P51151 2/20 0.48
NPC1 O15118 1/20 0.48
LMNA P02545 1/20 0.48
SYK P43405 1/20 0.45
TAOK1 Q7L7X3 4/20 0.44
TAOK3 Q9H2K8 3/20 0.44
ADORA2A P29274 1/20 0.44
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
GAA P10253 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3423865 1.00 MTNR1A (0.57) MTNR1AMTNR1BP2RX7RAB9ANPC1
SCHEMBL3802378 0.93 RAB9A (0.49) MTNR1AMTNR1BP2RX7RAB9ANPC1
SCHEMBL6523052 0.85 MTNR1A (0.53) MTNR1AMTNR1BRAB9ASYKADORA2A
SCHEMBL3391287 0.85 MTNR1A (0.53) MTNR1AMTNR1BRAB9ASYKADORA2A
SCHEMBL12709415 0.82 P2RX7 (0.61) P2RX7RAB9ANPC1KDM4EALDH1A1
SCHEMBL3796915 0.78 ALDH1A1 (0.48) MTNR1AMTNR1BRAB9ANPC1LMNA
SCHEMBL3393766 0.78 MTNR1A (0.51) MTNR1AMTNR1BRAB9ANPC1LMNA
SCHEMBL3391235 0.78 MTNR1A (0.51) MTNR1AMTNR1BRAB9ANPC1LMNA
SCHEMBL3394258 0.78 MTNR1A (0.60) MTNR1AMTNR1BTAOK1TAOK3ADORA2A
SCHEMBL3394439 0.78 MTNR1A (0.60) MTNR1AMTNR1BTAOK1TAOK3ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1370530-B1 ACYLATED 1,2,3,4-TETRAHYDRONAPHTHYL AMINES AND THEIR USE AS PHARMACEUTICAL SANOFI AVENTIS DEUTSCHLAND (DE) 2010-12-29 EP disclosed
US-6949556-B2 Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical agents AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-09-27 US disclosed
EP-1370530-A1 ACYLATED 1,2,3,4-TETRAHYDRONAPHTHYL AMINES AND THEIR USE AS PHARMACEUTICAL Aventis Pharma Deutschland GmbH (DE) 2003-12-17 EP disclosed
US-20030022935-A1 Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical agents SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2003-01-30 US disclosed
WO-2002064565-A1 ACYLATED 1,2,3,4-TETRAHYDRONAPHTHYL AMINES AND THEIR USE AS PHARMACEUTICAL AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030022935-A1 Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical agents VEGFA, EDNRA, NR1H2 MTNR1A 604/4885MTNR1B 448/4885P2RX7 4701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.